SUBSCRIBE: Print / Digital / eNewsletter
A new hope for plaque psoriasis patients is on the horizon, suggests newly published phase 3 results from a study examining skin clearance in patients taking bimekizumab. (Milan Lipowski - stock.adobe.com)
Newly published results from a phase 3 study demonstrate the superiority of bimekizumab over adalimumab for plaque psoriasis.
A recent study shows promising results for using ultrasound to examine hand tendon and joint inflammation in psoriatic arthritis patients.
Researchers recently undertook an epidemiologic study to investigate the prevalence of palmoplantar pustulosis (PPP) and co-existing plaque psoriasis. Read what they discovered in this article.
Pediatric psoriasis patients may experience comorbidities, including psychiatric comorbidities, at a greater rate than children without the disease, according to a recent study.
Researchers performed a systematic review of available reports on the therapeutic benefit of interleukin (IL)-17/T-helper 17 (Th17) axis inhibitors in patients with generalized pustular psoriasis (GPP). Read what they discovered in this article.
A recent, extreme case of psoriasis demonstrates how socioeconomic factors can lead to inadequate disease control. The solution? A personalized treatment plan, says the study authors.
Psoriasis often has a greater impact on quality of life in patients with skin of color as the condition and its treatment can result in long-lasting pigmentary changes.
The 2019 joint American Academy of Dermatology and National Psoriasis Foundation phototherapy treatment of psoriasis guidelines comprehensively updates dermatologists and other providers on the state-of-the art use of various light modalities to treat psoriasis patients.
Oral health, habits and diet may influence disease severity in psoriasis, says a study published in the Dermatology Online Journal.
Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
